INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $138,000 | -96.6% | 10,000 | -96.0% | 0.01% | -95.5% |
| Q4 2021 | $4,072,000 | +21.7% | 250,000 | +11.0% | 0.22% | -9.8% |
| Q3 2021 | $3,346,000 | +7.5% | 225,200 | +246.5% | 0.24% | +76.8% |
| Q2 2020 | $3,112,000 | -21.6% | 65,000 | +2.8% | 0.14% | -44.8% |
| Q1 2020 | $3,969,000 | +100.3% | 63,200 | +295.0% | 0.25% | +133.6% |
| Q4 2019 | $1,982,000 | +66.1% | 16,000 | +6.7% | 0.11% | +114.0% |
| Q2 2019 | $1,193,000 | -99.3% | 15,000 | -99.0% | 0.05% | -99.2% |
| Q1 2019 | $162,200,000 | +92.8% | 1,449,900 | +73.7% | 5.97% | +3.6% |
| Q4 2018 | $84,136,000 | +35.0% | 834,600 | +69.3% | 5.77% | +87.1% |
| Q3 2018 | $62,340,000 | +475.9% | 493,000 | +282.2% | 3.08% | +278.2% |
| Q2 2018 | $10,824,000 | – | 129,000 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |